Clovis Oncology Seeks $149.5 Million IPO
This article was originally published in The Pink Sheet Daily
The Colorado cancer drug maker is seeking financing through the public capital markets.
You may also be interested in...
Third Rock is the sole Series A investor in MyoKardia, which plans to use personalized medicine to treat hypertrophic and dilated cardiomyopathies.
Biopharma start-ups raised $693 million in Q4 2011, up 131% from Q3. Device companies brought in $111 million, and diagnostics firms raised $120 million total, $96 million of which was from Biocartis’ Series C. Cancer was the most prevalent therapeutic area for biopharma alliances. And in great contrast to Q3’s one M&A deal involving a start-up company, Q4 saw nine start-up acquisitions.
Talk to any Big Pharma business development executive about deal-making trends for more than 15 minutes and the word out-licensing is bound to crop up. Major drugmakers are moving beyond the rhetoric and actually giving up rights to individual assets that heretofore would have been deemed too valuable to merit out-licensing -- but with qualifications.